Do analysts rate ZYBT or ASMB?

Assembly Biosciences has a consensus target price of $44.00, suggesting a potential upside of 64.55%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has preferable valuation and earnings, ZYBT or ASMB?

Assembly Biosciences has lower revenue, but higher earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.73 -$9.98M N/A N/A Assembly Biosciences $71.10M 5.98 -$6.12M -$0.11 N/A

Do analysts prefer CGC or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CGC or ZYBT?

Zhengye Biotechnology has lower revenue, but higher earnings than Canopy Growth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Canopy Growth $251.01M 1.70 -$190.29M -$0.45 N/A Zhengye Biotechnology $116.36M 0.73 -$9.98M N/A N/A

Does the media favor CGC or ZYBT?

In the previous week, Canopy Growth had 11 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 16 mentions for Canopy Growth and 5 mentions for Zhengye Biotechnology. Canopy Growth's average media sentiment score of 1.06 beat Zhengye Biotechnology's score of 0.29 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 9 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ZYBT or EOLS?

Evolus has a consensus target price of $14.50, indicating a potential upside of 91.55%. Given Evolus' stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings and valuation, ZYBT or EOLS?

Zhengye Biotechnology has higher earnings, but lower revenue than Evolus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.73 -$9.98M N/A N/A Evolus $297.18M 1.68 -$51.64M -$0.52 N/A

Is ZYBT or EOLS more profitable?

Zhengye Biotechnology has a net margin of 0.00% compared to Evolus' net margin of -10.85%. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Evolus -10.85% N/A -13.00%

Does the media refer more to ZYBT or EOLS?

In the previous week, Evolus had 9 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 14 mentions for Evolus and 5 mentions for Zhengye Biotechnology. Evolus' average media sentiment score of 0.32 beat Zhengye Biotechnology's score of 0.29 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ZYBT or ENTA?

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 46.89%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better valuation and earnings, ZYBT or ENTA?

Zhengye Biotechnology has higher revenue and earnings than Enanta Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.73 -$9.98M N/A N/A Enanta Pharmaceuticals $65.32M 6.15 -$81.89M -$2.59 N/A

Does the media refer more to ZYBT or ENTA?

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 5 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.34 beat Zhengye Biotechnology's score of 0.29 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend ZYBT or AVIR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, ZYBT or AVIR?

Zhengye Biotechnology has higher revenue and earnings than Atea Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $116.36M 0.73 -$9.98M N/A N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is ZYBT or AVIR more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Atea Pharmaceuticals N/A -57.01% -51.49%

Does the media prefer ZYBT or AVIR?

In the previous week, Zhengye Biotechnology had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Zhengye Biotechnology's score of 0.29 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zhengye Biotechnology (ZYBT) Competitors

$1.80 -0.09 (-4.76%)

As of 04:00 PM Eastern

Compare

ZYBT vs. ASMB, CGC, EOLS, ENTA, and AVIR

Should you buy Zhengye Biotechnology stock or one of its competitors? MarketBeat compares Zhengye Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zhengye Biotechnology include Assembly Biosciences (ASMB), Canopy Growth (CGC), Evolus (EOLS), Enanta Pharmaceuticals (ENTA), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceuticals" industry.

How does Zhengye Biotechnology compare to Assembly Biosciences?

Zhengye Biotechnology (NASDAQ:ZYBT) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Zhengye Biotechnology had 5 more articles in the media than Assembly Biosciences. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 0 mentions for Assembly Biosciences. Zhengye Biotechnology's average media sentiment score of 0.29 beat Assembly Biosciences' score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Assembly Biosciences	Neutral

Zhengye Biotechnology has a beta of -2.72, suggesting that its share price is 372% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

19.9% of Assembly Biosciences shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Assembly Biosciences has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.73	-$9.98M	N/A	N/A
Assembly Biosciences	$71.10M	5.98	-$6.12M	-$0.11	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Zhengye Biotechnology's return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Assembly Biosciences has a consensus target price of $44.00, suggesting a potential upside of 64.55%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Assembly Biosciences beats Zhengye Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

In the previous week, Canopy Growth had 11 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 16 mentions for Canopy Growth and 5 mentions for Zhengye Biotechnology. Canopy Growth's average media sentiment score of 1.06 beat Zhengye Biotechnology's score of 0.29 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	9 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhengye Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zhengye Biotechnology has lower revenue, but higher earnings than Canopy Growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.70	-$190.29M	-$0.45	N/A
Zhengye Biotechnology	$116.36M	0.73	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Zhengye Biotechnology's return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.59%	-14.36%
Zhengye Biotechnology	N/A	N/A	N/A

3.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Canopy Growth has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.72, suggesting that its share price is 372% less volatile than the broader market.

Summary

Canopy Growth beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Evolus?

Zhengye Biotechnology (NASDAQ:ZYBT) and Evolus (NASDAQ:EOLS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Evolus had 9 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 14 mentions for Evolus and 5 mentions for Zhengye Biotechnology. Evolus' average media sentiment score of 0.32 beat Zhengye Biotechnology's score of 0.29 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolus	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evolus has a consensus target price of $14.50, indicating a potential upside of 91.55%. Given Evolus' stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zhengye Biotechnology has higher earnings, but lower revenue than Evolus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.73	-$9.98M	N/A	N/A
Evolus	$297.18M	1.68	-$51.64M	-$0.52	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Evolus' net margin of -10.85%.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Evolus	-10.85%	N/A	-13.00%

Zhengye Biotechnology has a beta of -2.72, indicating that its share price is 372% less volatile than the broader market. Comparatively, Evolus has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

90.7% of Evolus shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Evolus beats Zhengye Biotechnology on 10 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Enanta Pharmaceuticals?

Zhengye Biotechnology (NASDAQ:ZYBT) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Zhengye Biotechnology has higher revenue and earnings than Enanta Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.73	-$9.98M	N/A	N/A
Enanta Pharmaceuticals	$65.32M	6.15	-$81.89M	-$2.59	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Zhengye Biotechnology's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Enanta Pharmaceuticals has a consensus price target of $20.29, indicating a potential upside of 46.89%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 5 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 0.34 beat Zhengye Biotechnology's score of 0.29 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zhengye Biotechnology has a beta of -2.72, suggesting that its stock price is 372% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Summary

Enanta Pharmaceuticals beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Atea Pharmaceuticals?

Zhengye Biotechnology (NASDAQ:ZYBT) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Zhengye Biotechnology's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zhengye Biotechnology has higher revenue and earnings than Atea Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$116.36M	0.73	-$9.98M	N/A	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Zhengye Biotechnology has a beta of -2.72, suggesting that its stock price is 372% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, Zhengye Biotechnology had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Zhengye Biotechnology's score of 0.29 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atea Pharmaceuticals beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$85.30M	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	N/A	788.51	269.75	24.73
Price / Sales	0.73	967.70	652.34	108.63
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	1.94	10.33	11.27	6.42
Net Income	-$9.98M	$2.77B	$3.45B	$347.12M
7 Day Performance	35.34%	2.04%	3.56%	2.48%
1 Month Performance	125.00%	-1.57%	-0.58%	-1.04%
1 Year Performance	-65.45%	191.33%	77.52%	23.22%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	0.5948 of 5 stars	$1.80 -4.8%	N/A	-63.7%	$85.30M	$116.36M	N/A	278	Gap Down
ASMB Assembly Biosciences	1.6295 of 5 stars	$26.45 -0.3%	$44.00 +66.4%	+11.3%	$421.71M	$72.30M	N/A	100	Gap Up
CGC Canopy Growth	1.3311 of 5 stars	$0.93 +0.1%	N/A	-22.4%	$417.79M	$251.01M	N/A	1,128	Positive News Earnings Report Analyst Upgrade
EOLS Evolus	2.3153 of 5 stars	$7.41 +19.9%	$14.50 +95.7%	+28.6%	$406.98M	$297.18M	N/A	170	Analyst Upgrade Gap Up High Trading Volume
ENTA Enanta Pharmaceuticals	2.1358 of 5 stars	$13.34 +0.9%	$20.29 +52.1%	+99.6%	$384.42M	$65.32M	N/A	160	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ASMB, CGC, EOLS, ENTA, and AVIR

How does Zhengye Biotechnology compare to Assembly Biosciences?

Summary

How does Zhengye Biotechnology compare to Canopy Growth?

Summary

How does Zhengye Biotechnology compare to Evolus?

Summary

How does Zhengye Biotechnology compare to Enanta Pharmaceuticals?

Summary

How does Zhengye Biotechnology compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ASMB, CGC, EOLS, ENTA, and AVIR

How does Zhengye Biotechnology compare to Assembly Biosciences?

Does the media refer more to ZYBT or ASMB?

Which has more risk & volatility, ZYBT or ASMB?

Do insiders & institutionals hold more shares of ZYBT or ASMB?

Which has preferable valuation and earnings, ZYBT or ASMB?

Is ZYBT or ASMB more profitable?

Do analysts rate ZYBT or ASMB?

Summary

How does Zhengye Biotechnology compare to Canopy Growth?

Does the media favor CGC or ZYBT?

Which has better earnings & valuation, CGC or ZYBT?

Do analysts prefer CGC or ZYBT?

Is CGC or ZYBT more profitable?

Do institutionals & insiders have more ownership in CGC or ZYBT?

Which has more risk & volatility, CGC or ZYBT?

Summary

How does Zhengye Biotechnology compare to Evolus?

Does the media refer more to ZYBT or EOLS?

Do analysts recommend ZYBT or EOLS?

Which has stronger earnings and valuation, ZYBT or EOLS?

Is ZYBT or EOLS more profitable?

Which has more risk & volatility, ZYBT or EOLS?

Do institutionals and insiders believe in ZYBT or EOLS?

Summary

How does Zhengye Biotechnology compare to Enanta Pharmaceuticals?

Which has better valuation and earnings, ZYBT or ENTA?

Is ZYBT or ENTA more profitable?

Do analysts recommend ZYBT or ENTA?

Do insiders and institutionals believe in ZYBT or ENTA?

Does the media refer more to ZYBT or ENTA?

Which has more volatility & risk, ZYBT or ENTA?

Summary

How does Zhengye Biotechnology compare to Atea Pharmaceuticals?

Do analysts recommend ZYBT or AVIR?

Is ZYBT or AVIR more profitable?

Do insiders & institutionals believe in ZYBT or AVIR?

Which has higher valuation & earnings, ZYBT or AVIR?

Which has more volatility and risk, ZYBT or AVIR?

Does the media prefer ZYBT or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools